IL-23 antibody for inflammatory bowel disease
Part of Digestive system clinical trials.
This trial tests a new antibody drug (IL-23 inhibitor) for people with Crohn's disease or ulcerative colitis. It aims to see if the drug is safe and effective. You may be able to join if you have moderate to severe disease and have not had certain bowel surgeries or infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with Crohn's disease or ulcerative colitis.
- You have not had any major bowel surgery (like removing part of the small or large intestine).
- You do not have active infections like tuberculosis, shingles, or cytomegalovirus.
- You have no history of cancer or lymphoma.
- You agree to use birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with moderate-to-severe Crohn's disease who are starting a newer type of biologic medication called IL-23 inhibitors (guselkumab or risankizumab). Researchers want to understand how well these drugs work in real-world clinical practice and compare their effectiveness to other treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to treat inflammatory bowel disease (IBD) that has not responded to standard treatments. The therapy is engineered to target specific immune cells involved in IBD inflammation.
This study is gathering information on how well Il-23 inhibitors work and how safe they are for people with ulcerative colitis or Crohn's disease in China. It is a real-world study, meaning it looks at people using these drugs in everyday medical practice.
This trial uses special fluorescent versions of adalimumab and risankizumab to see inflammation in the bowel during an endoscopic procedure. It may help find out which treatment works best for each person's inflammation.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
This trial tests an experimental drug (ISM5411) for people with active ulcerative colitis. The goal is to see if the drug can reduce inflammation and improve symptoms.
Hear when a new Crohn's Disease and Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.